Research & Development
ESMO data buttress MCED test potential for the undiagnosed
One of the latest studies reported at ESMO showed that an MCED test could detect a cancer signal in 1.4% of 6,621 people ages 50 years and over who were not known to have cancer, and that cancer was later confirmed in 38% of those who received a positive MCED test.
September 11, 2022
Artemis signs $250M deal for liquid biopsy tests with Datar
The contract gives Artemis DNA the exclusivity to commercialize and distribute the liquid biopsy tests Trucheck Pragma and Cancertrack in the U.S. and Vietnam. Trucheck Pragma is a noninvasive blood-based screening test for lung, stomach, colon, pancreas, prostate, breast, and ovarian cancers; Cancertrack is a cancer monitoring test that allows patients to evaluate response/resistance during treatment and monitor recurrence of cancer.
May 15, 2022
Artemis expands NGS genetic testing into Vietnam
Artemis DNA will begin offering cancer screening in Vietnam through a partnership with Datar Cancer Genetics, a cancer research firm based in India and the U.K., focused on noninvasive techniques for diagnosis and treatment choices.
April 12, 2022
Dr. Elizabeth Stern: A pioneer in cytopathology screening
March 28, 2022
Google reports pathology AI helps predict survival in cancer patients
The deep-learning system was developed and tested using histopathology slides for patients with 10 cancer types -- including bladder cancer, invasive breast cancer, and head and neck squamous cell carcinoma -- drawing from publicly available data from the Cancer Genome Atlas (TCGA) program.
June 17, 2020
Page 1 of 1